Mereo BioPharma (MREO) Current Assets (2017 - 2026)
Mereo BioPharma (MREO) posted quarterly Current Assets of $40.0 million for Q1 2026, down 40.16% year-over-year from $66.9 million in Q1 2025, and down 11.08% quarter-over-quarter from $45.0 million in Q4 2025.
Mereo BioPharma (MREO) Current Assets (2017 - 2026) Analysis & Trends
Mereo BioPharma (MREO) has reported Current Assets for 10 consecutive years, with $40.0 million the latest figure, recorded in Q1 2026.
- In Q1 2026, Current Assets fell 40.16% year-over-year to $40.0 million; the TTM figure through Mar 2026 stood at $40.0 million (down 40.16% YoY), while the FY2025 annual figure was $45.0 million, down 39.78% from the prior year.
- Current Assets fell to $40.0 million in Q1 2026 per MREO's latest filing, from $45.0 million in the prior quarter.
- Across five years, Current Assets topped out at $103.0 million in Q2 2022 and bottomed at $40.0 million in Q1 2026.
- Historically, Current Assets has averaged $67.9 million across 5 years, with a median of $66.9 million in 2025.
- Annual changes were most pronounced in 2022 — Current Assets slumped 45.57% — and 2024, when it soared 38.43%.
- Mereo BioPharma's Current Assets stood at $72.9 million in 2022, then slipped by 12.51% to $63.8 million in 2023, then increased by 17.26% to $74.8 million in 2024, then sank by 39.78% to $45.0 million in 2025, then fell by 11.08% to $40.0 million in 2026.
- Business Quant data shows MREO's Current Assets at $40.0 million in Q1 2026, $45.0 million in Q4 2025, and $52.4 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Current Assets (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.88 Bn | 132.03 Bn | 2.84 Bn | 12.54 Bn |
| 2 | Regeneron Pharmaceuticals | 86.62 Bn | 78.62 Bn | 3.93 Bn | 18.45 Bn |
| 3 | Argenx Se | 65.28 Bn | 60.10 Bn | 1.37 Bn | 8.07 Bn |
| 4 | Moderna | 61.39 Bn | 56.25 Bn | 52.00 Mn | 5.82 Bn |
| 5 | BeOne Medicines | 42.11 Bn | 37.01 Bn | 1.53 Bn | 7.22 Bn |
| 6 | Alnylam Pharmaceuticals | 31.37 Bn | 28.06 Bn | 992.69 Mn | 4.62 Bn |
| 7 | BioNTech SE | 28.76 Bn | 10.37 Bn | 668.28 Mn | 18.80 Bn |
| 8 | Insmed | 27.46 Bn | 26.30 Bn | 358.27 Mn | 1.63 Bn |
| 9 | Royalty Pharma | 27.24 Bn | 26.41 Bn | - | 1.76 Bn |
| 10 | Mereo BioPharma | 46.65 Mn | 46.65 Mn | - | 33.40 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 33.40 Mn |
| Mar 31, 2026 | 40.03 Mn |
| Dec 31, 2025 | 45.02 Mn |
| Sep 30, 2025 | 52.41 Mn |
| Jun 30, 2025 | 61.42 Mn |
| Mar 31, 2025 | 66.90 Mn |
| Dec 31, 2024 | 74.76 Mn |
| Sep 30, 2024 | 86.72 Mn |
| Jun 30, 2024 | 93.94 Mn |
| Mar 31, 2024 | 53.50 Mn |
| Dec 31, 2023 | 63.76 Mn |
| Jun 30, 2023 | 67.86 Mn |
| Dec 31, 2022 | 72.88 Mn |
| Jun 30, 2022 | 103.02 Mn |
| Dec 31, 2021 | 133.89 Mn |
| Jun 30, 2021 | 168.20 Mn |
| Dec 31, 2020 | 39.25 Mn |
| Jun 30, 2020 | 82.80 Mn |
| Dec 31, 2019 | 39.13 Mn |
| Jun 30, 2019 | 62.88 Mn |